Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Grants Idera Pharmaceuticals Fast Track Designation | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

FDA Grants Idera Pharmaceuticals Fast Track Designation

IMO-2125 focuses on the treatment of PD-1 refractory metastatic melanoma

By: Betsy Louda

, Contract Pharma

The U.S. Food and Drug Administration has granted Fast Track designation to Idera Pharmaceuticals’ lead development candidate, IMO-2125. The treatment is to be used in combination with Ipilimumab for the treatment of anti-PD-1 refractory metastatic melanoma in combination with ipilimumab therapy.

IMO-2125 received orphan drug designation from the FDA in 2017 for the treatment of melanoma Stages IIb to IV. It signals the immune system to create and activate cancer-fighting cells (T-cells) to target solid tumors in refractory melanoma patients.

“This Fast Track designation represents another positive step for the development of IMO-2125 and is a clear recognition of the serious unmet need that exists for patients who do not benefit from anti-PD-1 therapy,” stated Joanna Horobin, M.B., Ch.B., Idera’s chief medical officer. “We’re thrilled with the dramatic response rate that has been observed to date so far with IMO-2125 in combination with ipilimumab and are eager to continue enrolling more patients through both the Phase 2 expansion of our ongoing trial and initiating the Phase 3 trial early next year.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics